iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/8326334/
A double blind study on azathioprine efficacy in multiple sclerosis: final report - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1993 May;240(5):295-8.
doi: 10.1007/BF00838165.

A double blind study on azathioprine efficacy in multiple sclerosis: final report

Affiliations
Clinical Trial

A double blind study on azathioprine efficacy in multiple sclerosis: final report

C Milanese et al. J Neurol. 1993 May.

Abstract

Forty patients, affected by multiple sclerosis with remitting-relapsing or progressive course, were included in a double blind study of treatment with azathioprine (2 mg/kg/day) lasting 3 years. The mean changes on the Expanded Disability Status Scale and in the survival analysis show a trend in favour of azathioprine both in slowing disease progression and reducing relapse frequency. These findings, repeatedly observed in similar trials, indicate that azathioprine should be used in the treatment of multiple sclerosis.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Lancet. 1984 Feb 4;1(8371):276-7 - PubMed
    1. Ann N Y Acad Sci. 1965 Mar 31;122:552-68 - PubMed
    1. J Neurol Sci. 1982 Jun;54(3):377-94 - PubMed
    1. Neurology. 1990 Jun;40(6):971-5 - PubMed
    1. Neurology. 1988 Jul;38(7 Suppl 2):20-3 - PubMed

Publication types

LinkOut - more resources